SG10202011624SA - Compositions and methods related to engineered fc constructs - Google Patents

Compositions and methods related to engineered fc constructs

Info

Publication number: SG10202011624SA
Authority: SG; Singapore
Prior art keywords: engineered; constructs; compositions; methods related; methods
Prior art date: 2016-05-23

Application number

SG10202011624SA

Inventor

Jonathan C Lansing

Carlos J Bosques

Daniel Ortiz

Original Assignee

Momenta Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-05-23

Filing date

2017-05-23

Publication date

2021-01-28

2017-05-23 Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc

2021-01-28 Publication of SG10202011624SA publication Critical patent/SG10202011624SA/en

Links

239000000203 mixture Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0684—Cells of the urinary tract or kidneys
- C12N5/0686—Kidney cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

SG10202011624SA 2016-05-23 2017-05-23 Compositions and methods related to engineered fc constructs SG10202011624SA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201662340322P	2016-05-23	2016-05-23
US201762443451P	2017-01-06	2017-01-06

Publications (1)

Publication Number	Publication Date
SG10202011624SA true SG10202011624SA (en)	2021-01-28

Family

ID=60412547

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
SG10202011624SA SG10202011624SA (en)	2016-05-23	2017-05-23	Compositions and methods related to engineered fc constructs
SG11201810465RA SG11201810465RA (en)	2016-05-23	2017-05-23	Compositions and methods related to engineered fc constructs
SG11201810466PA SG11201810466PA (en)	2016-05-23	2017-05-23	Compositions and methods related to engineered fc constructs

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
SG11201810465RA SG11201810465RA (en)	2016-05-23	2017-05-23	Compositions and methods related to engineered fc constructs
SG11201810466PA SG11201810466PA (en)	2016-05-23	2017-05-23	Compositions and methods related to engineered fc constructs

Country Status (12)

Country	Link
US (4)	US11623964B2 (en)
EP (2)	EP3484514B1 (en)
JP (4)	JP7045333B6 (en)
KR (3)	KR102462084B1 (en)
CN (3)	CN109789203B (en)
AU (2)	AU2017272111A1 (en)
BR (2)	BR112018074032A2 (en)
CA (2)	CA3025306A1 (en)
DK (1)	DK3484514T3 (en)
IL (3)	IL309293A (en)
SG (3)	SG10202011624SA (en)
WO (2)	WO2017205434A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP4299595A3 (en)	2014-05-02	2024-03-13	Momenta Pharmaceuticals, Inc.	Compositions and methods related to engineered fc constructs
US11623964B2 (en)	2016-05-23	2023-04-11	Momenta Pharmaceuticals, Inc.	Compositions and methods related to engineered Fc constructs
SG11201906139VA (en)	2017-01-06	2019-08-27	Momenta Pharmaceuticals Inc	Compositions and methods related to engineered fc constructs
CN113395978A (en) *	2018-07-11	2021-09-14	动量制药公司	Compositions and methods related to engineered Fc-antigen binding domain constructs targeting CTLA-4
KR20210044218A (en) *	2018-07-11	2021-04-22	모멘타 파머슈티컬스 인코포레이티드	Compositions and methods related to CD38 targeting engineered Fc-antigen binding domain constructs
CN112996910A (en) *	2018-07-11	2021-06-18	动量制药公司	Compositions and methods related to engineered Fc-antigen binding domain constructs targeting PD-L1
CA3106254A1 (en) *	2018-07-11	2020-01-16	Momenta Pharmaceuticals, Inc.	Compositions and methods related to engineered fc-antigen binding domain constructs
KR20210043583A (en) *	2018-07-11	2021-04-21	모멘타 파머슈티컬스 인코포레이티드	Compositions and methods related to engineered Fc-antigen binding domain constructs
AU2019302662A1 (en) *	2018-07-11	2021-02-25	Momenta Pharmaceuticals, Inc.	Compositions and methods related to engineered Fc-antigen binding domain constructs targeted to CCR4
MX2021000280A (en) *	2018-07-11	2021-11-12	Momenta Pharmaceuticals Inc	COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS.
CN113164591A (en) *	2018-07-11	2021-07-23	动量制药公司	Compositions and methods relating to engineered Fc-antigen binding domain constructs
CN113544043A (en)	2019-03-08	2021-10-22	株式会社万都	Rack-driven electric power-assisted steering device
CN114401985A (en)	2019-09-13	2022-04-26	康诺贝林伦瑙有限公司	Recombinant IgG Fc multimers for the treatment of immune complex-mediated renal disorders
US20230025806A1 (en)	2019-12-06	2023-01-26	CSL Behring Lengnau AG	Stable compositions of fc multimers
CN111808170A (en) *	2020-06-29	2020-10-23	江苏为真生物医药技术股份有限公司	Polypeptide, HLA-DR protein, preparation method and application thereof
EP4255933A1 (en) *	2020-12-07	2023-10-11	Invetx, Inc.	Compositions for increasing half-life of a therapeutic agent in livestock animals and methods of use

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2556219B1 (en)	1983-12-07	1987-06-26	Merieux Inst	NEW IMMUNOMODULATOR DRUG BASED ON HUMAN IGG FC FRAGMENTS
US5426641A (en)	1994-01-28	1995-06-20	Bell Communications Research, Inc.	Adaptive class AB amplifier for TDMA wireless communications systems
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
AU3804397A (en)	1996-06-14	1998-01-07	Smithkline Beecham Corporation	Hexameric fusion proteins and uses therefor
US20090074839A1 (en)	1997-01-22	2009-03-19	Marton Milankovits	Pharmaceutical Compositions Primarily for the Treatment and Prevention of Genitourinary Infections and their Extragenital Complications
US7951917B1 (en)	1997-05-02	2011-05-31	Genentech, Inc.	Method for making multispecific antibodies having heteromultimeric and common components
US20020062010A1 (en) *	1997-05-02	2002-05-23	Genentech, Inc.	Method for making multispecific antibodies having heteromultimeric and common components
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
ATE337403T1 (en)	1999-12-24	2006-09-15	Genentech Inc	METHOD AND COMPOUNDS FOR EXTENSING THE HALF-LIFE TIMES IN THE EXCRETION OF BIOACTIVE COMPOUNDS
US20050089932A1 (en) *	2001-04-26	2005-04-28	Avidia Research Institute	Novel proteins with targeted binding
WO2005077981A2 (en)	2003-12-22	2005-08-25	Xencor, Inc.	Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
US10011858B2 (en)	2005-03-31	2018-07-03	Chugai Seiyaku Kabushiki Kaisha	Methods for producing polypeptides by regulating polypeptide association
GB0614780D0 (en)	2006-07-25	2006-09-06	Ucb Sa	Biological products
PE20081140A1 (en) *	2006-10-25	2008-09-22	Amgen Inc	THERAPEUTIC AGENTS BASED ON PEPTIDES DERIVED FROM TOXINS
BRPI0620639A2 (en)	2006-12-21	2011-11-22	Micromet Ag	bispecific single chain antibodies and pharmaceutical composition comprising the same
WO2008131242A1 (en)	2007-04-18	2008-10-30	Zymogenetics, Inc.	Single chain fc, methods of making and methods of treatment
NZ581395A (en)	2007-05-14	2012-08-31	Biogen Idec Inc	Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
CN107011445B (en) *	2007-06-01	2021-06-29	马里兰大学巴尔的摩分校	Immunoglobulin constant region Fc receptor binding agents
PT2235064E (en)	2008-01-07	2016-03-01	Amgen Inc	Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
WO2009123894A2 (en)	2008-04-02	2009-10-08	Macrogenics, Inc.	Her2/neu-specific antibodies and methods of using same
JP2012504660A (en)	2008-10-06	2012-02-23	ユニバーシティオブシカゴ	Compositions and methods related to bacterial EAP, EMP and / or ADSA proteins
WO2010065578A2 (en)	2008-12-04	2010-06-10	Leukosight Inc.	POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (IgG) AND METHODS OF USING THE SAME
ES2550384T3 (en)	2008-12-18	2015-11-06	Dana-Farber Cancer Institute, Inc.	NKG2D-Fc for immunotherapy
EP2389192A4 (en)	2009-01-23	2013-01-16	Biogen Idec Inc	Stabilized fc polypeptides with reduced effector function and methods of use
US20120064008A1 (en)	2009-05-20	2012-03-15	Bruce Zetter	Compositions for the treatment of metastatic cancer and methods of use thereof
AU2010249787A1 (en)	2009-05-20	2011-12-22	Theraclone Sciences, Inc.	Compositions and methods for the therapy and diagnosis of influenza
EP2448972A4 (en) *	2009-06-30	2012-11-28	Res Dev Foundation	Immunoglobulin fc polypeptides
RU2015153109A (en)	2009-09-16	2019-01-15	Дженентек, Инк.	SUPERSPIRAL AND / OR BINDING PROTEIN COMPLEXES AND THEIR APPLICATIONS
US9096877B2 (en)	2009-10-07	2015-08-04	Macrogenics, Inc.	Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
JP2013511281A (en)	2009-11-23	2013-04-04	アムジェンインコーポレイテッド	Monomeric antibody Fc
GB0922209D0 (en)	2009-12-18	2010-02-03	Univ Nottingham	Proteins, nucleic acid molecules and compositions
US9238080B2 (en) *	2010-05-21	2016-01-19	Merrimack Pharmaceuticals, Inc.	Bi-specific fusion proteins
MX2013000301A (en)	2010-07-09	2013-05-09	Biogen Idec Hemophilia Inc	Chimeric clotting factors.
CN103154036B (en)	2010-07-28	2016-05-11	格利克尼克股份有限公司	The fusion of natural human protein fragments is to produce orderly multimerization immunoglobulin FC composition
EP2603526A1 (en)	2010-08-13	2013-06-19	Medimmune Limited	Monomeric polypeptides comprising variant fc regions and methods of use
AU2011325833C1 (en)	2010-11-05	2017-07-13	Zymeworks Bc Inc.	Stable heterodimeric antibody design with mutations in the Fc domain
WO2012087746A1 (en) *	2010-12-23	2012-06-28	Janssen Biotech, Inc.	Active protease-resistant antibody fc mutants
AU2012227883A1 (en)	2011-03-17	2013-10-24	Ramot At Tel-Aviv University Ltd.	Bi- and monospecific, asymmetric antibodies and methods of generating the same
EA028804B1 (en)	2011-03-25	2018-01-31	Гленмарк Фармасьютикалс С.А.	Hetero-dimeric immunoglobulins
JP2015521589A (en)	2012-06-08	2015-07-30	バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎＭＡＩｎｃ．	Procoagulant compounds
WO2013192131A1 (en) *	2012-06-21	2013-12-27	Indiana University Research And Technology Corporation	Incretin receptor ligand polypeptide fc-region fusion polypeptides and conjugates with altered fc-effector function
CA2882296A1 (en) *	2012-08-20	2014-02-27	Gliknik Inc.	Molecules with antigen binding and polyvalent fc gamma receptor binding activity
EP2908914B1 (en) *	2012-10-17	2018-04-18	Liverpool School of Tropical Medicine	Immunomodulatory proteins
CN104558194B (en) *	2013-10-17	2018-04-27	泰州迈博太科药业有限公司	A kind of anti-CD20-Flex bifunctional fusion proteins, preparation method and the usage
US10137170B2 (en) *	2013-12-20	2018-11-27	Indiana University Research And Technology Corporation	Lipidated incretin receptor ligand human immunoglobulin Fc-region fusion polypeptides
JP6873701B2 (en)	2014-01-15	2021-05-19	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	Fc region mutant with modified FcRn binding properties
WO2015107026A1 (en)	2014-01-15	2015-07-23	F. Hoffmann-La Roche Ag	Fc-region variants with modified fcrn- and maintained protein a-binding properties
US20170081406A1 (en)	2014-03-05	2017-03-23	Ucb Biopharma Sprl	Multimeric fc proteins
JP6851200B2 (en)	2014-03-05	2021-03-31	ユーシービーバイオファルマエスアールエル	Multimeric Fc protein
EP4299595A3 (en)	2014-05-02	2024-03-13	Momenta Pharmaceuticals, Inc.	Compositions and methods related to engineered fc constructs
CN113549153A (en)	2014-05-29	2021-10-26	宏观基因有限公司	Trispecific binding molecules and methods of use thereof
WO2017151971A2 (en)	2016-03-02	2017-09-08	Momenta Pharmaceuticals, Inc.	METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
US11623964B2 (en)	2016-05-23	2023-04-11	Momenta Pharmaceuticals, Inc.	Compositions and methods related to engineered Fc constructs
SG11201906139VA (en) *	2017-01-06	2019-08-27	Momenta Pharmaceuticals Inc	Compositions and methods related to engineered fc constructs

2017
- 2017-05-23 US US16/303,831 patent/US11623964B2/en active Active
- 2017-05-23 WO PCT/US2017/034084 patent/WO2017205434A1/en unknown
- 2017-05-23 WO PCT/US2017/034087 patent/WO2017205436A1/en unknown
- 2017-05-23 BR BR112018074032-2A patent/BR112018074032A2/en unknown
- 2017-05-23 KR KR1020187037334A patent/KR102462084B1/en active IP Right Grant
- 2017-05-23 KR KR1020227037780A patent/KR102635635B1/en active IP Right Grant
- 2017-05-23 CA CA3025306A patent/CA3025306A1/en active Pending
- 2017-05-23 AU AU2017272111A patent/AU2017272111A1/en active Pending
- 2017-05-23 SG SG10202011624SA patent/SG10202011624SA/en unknown
- 2017-05-23 US US16/303,793 patent/US11155640B2/en active Active
- 2017-05-23 CN CN201780045710.8A patent/CN109789203B/en active Active
- 2017-05-23 CA CA3025310A patent/CA3025310A1/en active Pending
- 2017-05-23 SG SG11201810465RA patent/SG11201810465RA/en unknown
- 2017-05-23 JP JP2018561641A patent/JP7045333B6/en active Active
- 2017-05-23 EP EP17803463.3A patent/EP3484514B1/en active Active
- 2017-05-23 SG SG11201810466PA patent/SG11201810466PA/en unknown
- 2017-05-23 JP JP2018561639A patent/JP2019519527A/en not_active Withdrawn
- 2017-05-23 KR KR1020187037345A patent/KR102590061B1/en active IP Right Grant
- 2017-05-23 IL IL309293A patent/IL309293A/en unknown
- 2017-05-23 BR BR112018074056-0A patent/BR112018074056A2/en unknown
- 2017-05-23 IL IL263213A patent/IL263213B1/en unknown
- 2017-05-23 EP EP17803465.8A patent/EP3464376A4/en active Pending
- 2017-05-23 CN CN201780045688.7A patent/CN109963869A/en active Pending
- 2017-05-23 AU AU2017272109A patent/AU2017272109A1/en active Pending
- 2017-05-23 DK DK17803463.3T patent/DK3484514T3/en active
- 2017-05-23 IL IL263211A patent/IL263211B2/en unknown
- 2017-05-23 CN CN202210924611.XA patent/CN116063540A/en active Pending
2021
- 2021-10-01 US US17/491,677 patent/US20220049019A1/en active Pending
2022
- 2022-01-27 JP JP2022010912A patent/JP2022068176A/en active Pending
- 2022-03-18 JP JP2022044109A patent/JP7295301B2/en active Active
2023
- 2023-04-10 US US18/298,131 patent/US20240067757A1/en active Pending

Also Published As

Publication number	Publication date
KR20190021255A (en)	2019-03-05
US11155640B2 (en)	2021-10-26
AU2017272109A1 (en)	2019-01-17
KR102590061B1 (en)	2023-10-18
US20190284305A1 (en)	2019-09-19
SG11201810465RA (en)	2018-12-28
BR112018074032A2 (en)	2019-02-26
JP2022068176A (en)	2022-05-09
CN116063540A (en)	2023-05-05
WO2017205436A1 (en)	2017-11-30
EP3484514A1 (en)	2019-05-22
IL263211B2 (en)	2023-09-01
JP2019519528A (en)	2019-07-11
KR20220151025A (en)	2022-11-11
KR102635635B1 (en)	2024-02-14
CA3025310A1 (en)	2017-11-30
CA3025306A1 (en)	2017-11-30
KR20190026684A (en)	2019-03-13
EP3484514B1 (en)	2023-12-06
US11623964B2 (en)	2023-04-11
JP7295301B2 (en)	2023-06-20
WO2017205434A1 (en)	2017-11-30
US20240067757A1 (en)	2024-02-29
EP3464376A1 (en)	2019-04-10
US20220049019A1 (en)	2022-02-17
EP3464376A4 (en)	2020-03-18
US20210221917A1 (en)	2021-07-22
BR112018074056A2 (en)	2019-03-06
IL263213B1 (en)	2024-01-01
IL263211A (en)	2018-12-31
IL263213A (en)	2018-12-31
DK3484514T3 (en)	2024-01-29
EP3484514A4 (en)	2020-08-12
AU2017272111A1 (en)	2019-01-17
JP7045333B6 (en)	2022-05-06
JP2019519527A (en)	2019-07-11
IL263211B1 (en)	2023-05-01
JP2022095685A (en)	2022-06-28
IL309293A (en)	2024-02-01
KR102462084B1 (en)	2022-11-02
CN109789203B (en)	2022-08-05
JP7045333B2 (en)	2022-03-31
CN109789203A (en)	2019-05-21
SG11201810466PA (en)	2018-12-28
CN109963869A (en)	2019-07-02

Publication	Publication Date	Title
IL286367A (en)	2021-10-31	Compositions and methods related to engineered fc constructs
IL263211A (en)	2018-12-31	Compositions and methods related to engineered fc constructs
HK1247238B (en)	2019-08-16	Engineered crispr-cas9 compositions and methods of use
HK1259190A1 (en)	2019-11-29	Methods and compositions relating to chimeric antigen receptors
HRP20192145T1 (en)	2020-05-15	Carrier-antibody compositions and methods of making and using the same
EP3423572A4 (en)	2019-10-23	Methods related to engineered fc constructs
ZA201702794B (en)	2019-07-31	Cellulose-containing compositions and methods of making same
SG10202107391YA (en)	2021-08-30	Compositions and methods related to engineered fc constructs
ZA201701909B (en)	2018-05-30	Trichoderma compositions and methods of use
EP3119421A4 (en)	2017-11-29	Engineered chimeric pegylated adi and methods of use
HK1243404A1 (en)	2018-07-13	Tryptamide compositions and methods of use
GB201421430D0 (en)	2015-01-14	Antibodies to Adam17 and uses thereof